Omniose Receives $3.6M Grant from NIH

OmnioseA $3.6M grant was awarded to a company that is based in Saint Louis, MO and Boston, MA. It develops polysaccharide conjugate vaccinations against serious bacterial threats.

The National Institute of Allergy and Infectious Diseases of U.S. National Institutes of Health was the one who awarded the award.

The funds will be used by the company to develop a new product. Klebsiella pneumoniae vaccine. 

Omniose CEO Timothy Cooke and Chief Scientist Officer Christian Harding, Ph.D. have created a bioconjugate vaccine platform which allows for the precise attachment of almost any bacterial polysaccharide antigen (sugar) to engineered carrier proteins. E. coli cell. Company uses its bioconjugation platform for novel polysaccharide-protein conjugate vaccines K. pneumoniaeK. pneumoniae Produces multiple surface polysaccharides including a capsular polysaccharide or capsule and a lipopolysaccharide embellished with an O–antigen polysaccharide. Both the capsule and O-antigen are well-known. K. pneumoniae These factors were identified previously as potential vaccine candidates. This award, along with other NIH grants to Omniose, will fund the development and IND-enabling research of bioconjugate vaccinations that target clinically relevant capsular and O-antigen polysaccharides. K. pneumoniae.

Klebsiella pneumoniae is a leading cause of life-threatening sepsis in newborns as well as healthcare-associated infections, including pneumonia, bloodstream infections, wound or surgical site infections, and meningitis. The disease This resistance has been shown to be resistant to many antimicrobial classes and has been linked to an estimated 600,000 deaths in the world each year.



Leave a Comment